Abbott Laboratories (ABT) is Attracting Investor Attention: Here is What You Should Know

Abbott Laboratories (ABT) is under investor scrutiny as its stock has underperformed the S&P 500 over the past month, returning +0.5% versus the index's +5.2%. Current consensus estimates project a 9.7% EPS increase to $1.25 for the current quarter and revenue growth of 6.4% to $11.04 billion, with fiscal year 2024 and 2025 EPS expected to grow approximately 10%; however, the stock holds a Zacks Rank #3, suggesting near-term performance in line with the broader market.

Analysis

Abbott Laboratories (ABT), a prominent maker of infant formula, medical devices, and drugs, is currently attracting significant attention from Zacks.com visitors, yet its stock performance has been modest, with a +0.5% return over the past month, substantially underperforming the Zacks S&P 500 composite's +5.2% gain, while its industry, Zacks Medical - Products, saw a +0.3% rise. The company's near-term outlook is shaped by stable earnings estimate revisions, a factor Zacks prioritizes. For the current quarter, Abbott is projected to post earnings of $1.25 per share, a +9.7% year-over-year increase, with the consensus estimate remaining unchanged over the last 30 days. Similarly, full-year fiscal estimates point to robust growth, with EPS expected at $5.16 (+10.5% YoY) for the current year and $5.66 (+9.8% YoY) for the next, though these too have been static recently. This stability in estimates, alongside other factors, contributes to Abbott's Zacks Rank #3 (Hold), suggesting its stock may perform in line with the broader market in the near term. Revenue growth forecasts are also positive, with consensus sales for the current quarter at $11.04 billion (+6.4% YoY), and for the current and next fiscal years at $44.66 billion (+6.5% YoY) and $47.67 billion (+6.7% YoY) respectively. Abbott's last reported quarter saw revenues of $10.36 billion (+4% YoY), which was a -0.56% miss against consensus, although EPS of $1.09 surpassed estimates by +1.87%; historically, Abbott has beaten EPS estimates three times and revenue estimates twice in the last four quarters. The company's valuation, indicated by a Zacks Value Style Score of C, suggests it is trading at par with its peers.

Key Decisions for Investors

• Given Abbott's Zacks Rank #3 (Hold) and recent share price underperformance despite positive earnings forecasts, investors might consider maintaining existing positions rather than initiating aggressive new ones, as near-term market outperformance is not strongly signaled.
• Prospective investors should monitor for catalysts such as upward revisions in earnings estimates or stronger-than-expected revenue growth before committing capital, particularly as current valuation is deemed at par with peers and the stock has recently trailed the S&P 500.
• Particular attention should be paid to upcoming revenue results against the consensus estimate of $11.04 billion for the current quarter, as consistent achievement of the projected +6.4% to +6.7% revenue growth is crucial for realizing the anticipated 9.7% to 10.5% EPS expansion and justifying current growth expectations.